David Malcom Rodman - 09 Feb 2023 Form 3 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
09 Feb 2023
Net transactions value
$0
Form type
3
Filing time
09 Feb 2023, 18:53:14 UTC
Next filing
21 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MLYS Stock Option 09 Feb 2023 Common Stock 240,827 $0.5300 Direct F1
holding MLYS Stock Option 09 Feb 2023 Common Stock 304,730 $1.07 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F2 The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

Remarks:

Exhibit 24 Power of Attorney.